My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 254

    1.

    Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS).

    Blankenhorn DH, Azen SP, Kramsch DM, Mack WJ, Cashin-Hemphill L, Hodis HN, DeBoer LW, Mahrer PR, Masteller MJ, Vailas LI, Alaupovic P, Hirsch LJ; MARS Research Group.

    Ann Intern Med. 1993 Nov 15;119(10):969-76.PMID: 8214993 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    The Monitored Atherosclerosis Regression Study (MARS). Design, methods and baseline results.

    Cashin-Hemphill L, Kramsch DM, Azen SP, DeMets D, DeBoer LW, Hwang I, Vailas L, Hirsch LJ, Mack WJ, DeBoer L, et al.

    Online J Curr Clin Trials. 1992 Oct 23;Doc No 26:[9897 words; 83 paragraphs]. Erratum in: Online J Curr Clin Trials 1992 Nov 14;Doc No 29:[85 words; 2. PMID: 1343613 [PubMed - indexed for MEDLINE]Related articles

    3.

    Regression or reduction in progression of atherosclerosis, and avoidance of coronary events, with lovastatin in patients with or at high risk of cardiovascular disease: a review.

    Frisinghelli A, Mafrici A.

    Clin Drug Investig. 2007;27(9):591-604. Review.PMID: 17705568 [PubMed - indexed for MEDLINE]Related articles

    4.

    Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.

    Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, Zhao XQ, Bisson BD, Fitzpatrick VF, Dodge HT.

    N Engl J Med. 1990 Nov 8;323(19):1289-98.PMID: 2215615 [PubMed - indexed for MEDLINE]Related articles

    5.

    Benefits of lipid-lowering therapy in men with elevated apolipoprotein B are not confined to those with very high low density lipoprotein cholesterol.

    Stewart BF, Brown BG, Zhao XQ, Hillger LA, Sniderman AD, Dowdy A, Fisher LD, Albers JJ.

    J Am Coll Cardiol. 1994 Mar 15;23(4):899-906.PMID: 8106695 [PubMed - indexed for MEDLINE]Related articles

    6.

    [Lipid intervention and coronary heart disease in men less than 56 years of age. The Coronary Intervention Study: CIS]

    Rensing UF, Bestehorn HP, Roskamm H, Petersen J, Betz P, Spinder M, Benesch L, Schemeitat K, Blümchen G, Claus J, Wieland H, Böcker JF, Neiss A, Stiepel E, Mathes P, Kappenberger L, Braunagel K, Peters K, Meister G, Samek L, Schuon J, Leimenstoll B, Kiefer H.

    Z Kardiol. 1999 Apr;88(4):270-82. German. PMID: 10408031 [PubMed - indexed for MEDLINE]Related articles

    7.

    The effect of simvastatin on progression of coronary artery disease. The Multicenter coronary Intervention Study (CIS).

    Bestehorn HP, Rensing UF, Roskamm H, Betz P, Benesch L, Schemeitat K, Blümchen G, Claus J, Mathes P, Kappenberger L, Wieland H, Neiss A.

    Eur Heart J. 1997 Feb;18(2):226-34.PMID: 9043838 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    A comparison of quantitative computerized and human panel coronary endpoint measures: implications for the design of angiographic trials.

    Mack WJ, Azen SP, Dunn M, Hodis HN.

    Control Clin Trials. 1997 Apr;18(2):168-79.PMID: 9129860 [PubMed - indexed for MEDLINE]Related articles

    9.

    Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin.

    Hodis HN, Mack WJ, Azen SP, Alaupovic P, Pogoda JM, LaBree L, Hemphill LC, Kramsch DM, Blankenhorn DH.

    Circulation. 1994 Jul;90(1):42-9.PMID: 8026027 [PubMed - indexed for MEDLINE]Related articles

    10.

    Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.

    Waters D, Higginson L, Gladstone P, Kimball B, Le May M, Boccuzzi SJ, Lespérance J.

    Circulation. 1994 Mar;89(3):959-68.PMID: 8124836 [PubMed - indexed for MEDLINE]Related articles

    11.

    Effects of cigarette smoking on the angiographic evolution of coronary atherosclerosis. A Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) Substudy. CCAIT Study Group.

    Waters D, Lespérance J, Gladstone P, Boccuzzi SJ, Cook T, Hudgin R, Krip G, Higginson L.

    Circulation. 1996 Aug 15;94(4):614-21.PMID: 8772679 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

    Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr.

    JAMA. 1998 May 27;279(20):1615-22.PMID: 9613910 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Reduction in carotid arterial wall thickness using lovastatin and dietary therapy: a randomized controlled clinical trial.

    Hodis HN, Mack WJ, LaBree L, Selzer RH, Liu C, Liu C, Alaupovic P, Kwong-Fu H, Azen SP.

    Ann Intern Med. 1996 Mar 15;124(6):548-56.PMID: 8597317 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events.

    Whitney EJ, Krasuski RA, Personius BE, Michalek JE, Maranian AM, Kolasa MW, Monick E, Brown BG, Gotto AM Jr.

    Ann Intern Med. 2005 Jan 18;142(2):95-104.PMID: 15657157 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS).

    Jukema JW, Bruschke AV, van Boven AJ, Reiber JH, Bal ET, Zwinderman AH, Jansen H, Boerma GJ, van Rappard FM, Lie KI, et al.

    Circulation. 1995 May 15;91(10):2528-40.PMID: 7743614 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial.

    Alaupovic P, Mack WJ, Knight-Gibson C, Hodis HN.

    Arterioscler Thromb Vasc Biol. 1997 Apr;17(4):715-22.PMID: 9108785 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Effects of cholesterol lowering on the progression of coronary atherosclerosis in women. A Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) substudy.

    Waters D, Higginson L, Gladstone P, Boccuzzi SJ, Cook T, Lespérance J.

    Circulation. 1995 Nov 1;92(9):2404-10.PMID: 7586338 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS)

    Watts GF, Lewis B, Brunt JN, Lewis ES, Coltart DJ, Smith LD, Mann JI, Swan AV.

    Lancet. 1992 Mar 7;339(8793):563-9.PMID: 1347091 [PubMed - indexed for MEDLINE]Related articles

    19.

    Lack of effect of lovastatin on restenosis after coronary angioplasty. Lovastatin Restenosis Trial Study Group.

    Weintraub WS, Boccuzzi SJ, Klein JL, Kosinski AS, King SB 3rd, Ivanhoe R, Cedarholm JC, Stillabower ME, Talley JD, DeMaio SJ, et al.

    N Engl J Med. 1994 Nov 17;331(20):1331-7.PMID: 7935702 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Relation of progression of coronary artery atherosclerosis to risk of cardiovascular events (from the Monitored Atherosclerosis Regression Study).

    Vigen C, Hodis HN, Selzer RH, Mahrer PR, Mack WJ.

    Am J Cardiol. 2005 Jun 1;95(11):1277-82.PMID: 15904629 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity